Search Results

Targeting the cell surface U5 snRNP complex as a novel immunotherapy for AML

A major limitation of immunotherapy approaches for AML has been the lack of known targetable cell surface antigens specific to AML cells. This project…

Towards Risk-Adapted Therapeutic Strategies in CNS Lymphoma

This project will significantly advance the treatment and prevention of CNS lymphomas in two key areas. One, we will further develop and validate cand…

James Rubenstein

Targeting the Osteogenic Lineage as a Therapeutic Strategy in Multiple Myeloma

Multiple myeloma causes devastating bone disease characterised by focal bone lesions and generalise bone loss, which leads to an increase in bone frac…

Targeting the inflammatory GM-CSF pathway in high risk CMML

Chronic myelomonocytic leukemia (CMML) is a rare but poorly understood blood cancer often presenting with crippling inflammatory symptoms that frequen…

Peter Croucher

Peter trained at the University of Wales College of Medicine and Cambridge and Oxford Universities in the UK. In he joined Sheffield University and b…

Targeting the inflammasome in CMML

Overactivation of the inflammasome is seen in CMML and leads to worsening of this condition. We will explore the potential of a new inflammasome inhib…

A phase 2 study of BI-1808, a monoclonal antibody to TNFR2, as a single agent and in combination with pembrolizumab in patients with solid tumors and CTCL

In January , LLS made an equity investment in BioInvent to "Support Clinical Development of for NHL Indications and for Lymphoma Indications Includ…

A phase 2 expansion study of ICT01, an anti-BTN3A monoclonal antibody, in combination with azacitidine and venetoclax in patients with AML

In June , LLS made an equity investment in ImCheck Therapeutics to "Support Clinical Development of the ICT01 Program for Blood Cancer Indications."Im…

Therapeutic targeting of AML stem cells 2023

The goal of this SCOR project is to identify and eradicate the root cause of acute myeloid leukemia, the leukemia stem cell (LSC). In the previous cy…

Dissecting the mitochondrial alterations by aberrant NPM1 to the pathogenesis of myelodysplastic syndrome

Survival rates for those afflicted with MDS have not improved despite extensive effort to identify the key genetic events in its pathogenesis. This pr…

Pilot trial of microbial targeting to prevent myeloma

Our recent studies have identified specific bacteria that can potentially promote the growth of human myeloma tumor cells. We are now testing if eradi…

Targeting Myeloid Malignancies through IRAK4 Synthetic Lethality Dependencies

Based on our preliminary data, we hypothesize that IRAK4 inhibition leads to LSPC reprogramming in MDS and AML. Aim will evaluate the mechanism by wh…

Eric Vick

Eric J. Vick, MD, PhD is a at the University of Cincinnati who studies how blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syn…

Genomics of Diffuse Large B Cell Lymphoma: pervasive role of super-enhancer hypermutation in dysregulating oncogene expression

We recently identified a pervasive, pathogenically relevant mutational mechanism that targets (SE) in DLBCL, leading to target gene deregulation. Her…

Riccardo Dalla-Favera

Riccardo , MD, Professor of Pathology & Cell Biology, is the founder and Director of the Institute for Cancer Genetics at Columbia University.

Predicting progression in myeloproliferative neoplasm patients by reconstructing the history of disease in each patient

Blood cancers called myeloproliferative neoplasms occur when one of the blood stem cells picks up a mutation. Some patients stay in the chronic phase …

Sahand Hormoz

Dr. Hormoz is an Assistant Professor with the Department of Systems Biology at Harvard Medical School and Department of Data Science at the Cancer In…

Making an IMPACT on hematology care in Georgia: The Georgia Blood Cancer Trials Network (BCTN)

Winship Cancer Institute is the only Comprehensive Cancer Center in Georgia, the largest state by land area east of the Mississippi River, and 8th la…

Jonathon Cohen

Dr. Jonathon Cohen is an associate professor of hematology/oncology at Emory University and the lymphoma program at Winship Cancer Institute. He has …

Uncovering MGA-driven epigenetic reprogramming in Richter's syndrome

Richter’s syndrome (RS) is a critical complication of chronic lymphocytic leukemia. RS patients are refractory to most existing therapies and show a m…

Ramon Massoni-Badosa

Ramon , PhD is a graduate of Pompeu Fabra University, Barcelona in , and his PhD focused on applying genomics technologies to benchmark the effect of…

Investigating the dependency for protein synthesis in Venetoclax/Azacitidine-resistant acute myeloid leukemia

Relapsed and/or refractory acute myeloid leukemia (AML) display resistance to Venetoclax and Azacitidine (Ven/Aza) with approximately one third of pat…

Ana Vujovic

Ana Vujovic is a postdoctoral research fellow at the University of Colorado Anschutz Medical Campus. She completed her PhD under the mentorship of Dr.

TCR-like CARs targeting GvL mHAgs for the treatment of post-transplant AML relapse

AML recurrence is a devastating event after . I hypothesize that it could be counteracted through targeting of mHAgs via CARs. I will identify scFVs…